Bayer May Restructure After It Sells Off Material Sciences Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
The German multinational’s five recently launched pharmaceutical products are expected to continue to drive growth in 2015, while its transformation in to a life sciences-focused company should be completed by mid-2016 at the latest after it chooses between either an IPO or a spinoff for its material sciences division.